相关实验视频

Updated: Jul 4, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

诺克斯4-SH3YL1复合体与糖尿病病有关

Sae Rom Lee¹, Hye Eun Lee¹, Jung-Yeon Yoo¹

¹Department of Life Sciences, Ewha Womans University, Seoul 03760, Korea.

|February 6, 2024

概括

SH3YL1蛋白在糖尿病病的发展中至关重要. 在小鼠模型中抑制SH3YL1减少了纤维化和炎症,这表明它是糖尿病病的治疗标.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
分子生物学分子生物学
脏疾病的发病因子

背景情况:

由Nox4衍生过氧化产生的氧化应激会导致慢性病 (CKD),包括糖尿病病 (DN).
含有SH3域的Ysc84-like 1 (SH3YL1) 被确定为Nox4.4的细胞酶激活剂.

研究的目的:

调查SH3YL1在糖尿病病变的发病过程中的作用.
确定针对DN中的SH3YL1-Nox4相互作用的治疗潜力.

主要方法:

已建立的链毒素诱导的1型糖尿病小鼠模型具有全身SH3YL1淘汰赛 (KO) 和podocyte特定的SH3YL1条件KO (Nphs2-Cre/SH3YL1).
在糖尿病小鼠中评估了纤维化标志物,炎症性细胞因子,氧化应激和 podocyte 损失.
在人类DN患者样本中测量SH3YL1蛋白水平.

主要成果:

在小鼠中SH3YL1淘汰赛显著抑制了纤维化标志物,炎症性细胞因子,氧化应激,以及糖尿病病例中的 podocyte 损失.
在糖尿病脏病患者中观察到SH3YL1蛋白水平的增加.
SH3YL1-Nox4复合体与脏炎症和纤维化发展有关.

结论:

通过Nox4通路,SH3YL1在糖尿病病的发展中起着至关重要的作用.
向SH3YL1可能为治疗糖尿病病提供一种新的治疗策略.

关键词:

免疫学免疫学免疫学分子生物学分子生物学病理学病理学病理学

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...